Press Releases

Date	Title
4/6/20	GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
4/2/20	Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
3/30/20	Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
3/26/20	Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
3/25/20	Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
3/12/20	Vir Biotechnology Announces Intent to Collaborate with Biogen on Manufacturing of Antibodies to Potentially Treat COVID-19
3/11/20	Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
3/10/20	Vir Biotechnology to Present at Barclays Global Healthcare Conference
3/4/20	Vir and Alnylam Expand Collaboration to Advance RNAi Therapeutics for the Treatment of Coronavirus Infection, Including COVID-19
2/25/20	Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19

Vir - Investor Relations Menu